JP2025508840A - アルギナーゼ2ワクチン - Google Patents

アルギナーゼ2ワクチン Download PDF

Info

Publication number
JP2025508840A
JP2025508840A JP2024550216A JP2024550216A JP2025508840A JP 2025508840 A JP2025508840 A JP 2025508840A JP 2024550216 A JP2024550216 A JP 2024550216A JP 2024550216 A JP2024550216 A JP 2024550216A JP 2025508840 A JP2025508840 A JP 2025508840A
Authority
JP
Japan
Prior art keywords
cells
arg2
polypeptide
cancer
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508840A5 (cg-RX-API-DMAC7.html
Inventor
ハルド アンデルセン,マッズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2202547.2A external-priority patent/GB202202547D0/en
Priority claimed from GBGB2213372.2A external-priority patent/GB202213372D0/en
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2025508840A publication Critical patent/JP2025508840A/ja
Publication of JP2025508840A5 publication Critical patent/JP2025508840A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024550216A 2022-02-24 2023-02-23 アルギナーゼ2ワクチン Pending JP2025508840A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2202547.2A GB202202547D0 (en) 2022-02-24 2022-02-24 Arginase 2 vaccine
GB2202547.2 2022-02-24
GBGB2213372.2A GB202213372D0 (en) 2022-09-13 2022-09-13 Arginase 2 vaccine
GB2213372.2 2022-09-13
PCT/EP2023/054568 WO2023161346A1 (en) 2022-02-24 2023-02-23 Arginase 2 vaccine

Publications (2)

Publication Number Publication Date
JP2025508840A true JP2025508840A (ja) 2025-04-10
JP2025508840A5 JP2025508840A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=85415242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550216A Pending JP2025508840A (ja) 2022-02-24 2023-02-23 アルギナーゼ2ワクチン

Country Status (9)

Country Link
US (1) US20250161422A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482518A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508840A (cg-RX-API-DMAC7.html)
KR (1) KR20240159833A (cg-RX-API-DMAC7.html)
CN (1) CN119110729A (cg-RX-API-DMAC7.html)
AU (1) AU2023223567A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250919A1 (cg-RX-API-DMAC7.html)
IL (1) IL315164A (cg-RX-API-DMAC7.html)
WO (1) WO2023161346A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
PL3522905T3 (pl) 2016-10-07 2025-01-07 Io Biotech Aps Immunogenne peptydy arginazowe
AU2019201463A1 (en) * 2018-03-09 2019-09-26 Nantomics, Llc Srm/mrm assays for profiling tumor tissue
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
US20210382068A1 (en) * 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
GB201818576D0 (en) 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Also Published As

Publication number Publication date
IL315164A (en) 2024-10-01
US20250161422A1 (en) 2025-05-22
CA3250919A1 (en) 2023-08-31
CN119110729A (zh) 2024-12-10
EP4482518A1 (en) 2025-01-01
AU2023223567A1 (en) 2024-08-15
KR20240159833A (ko) 2024-11-06
WO2023161346A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
AU2020287902B2 (en) TGF-beta vaccine
US20250388674A1 (en) Immunogenic arginase 2 polypeptides
US20250205318A1 (en) Arginase1 polypeptides
JP4926714B2 (ja) Bcl−2ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
US20250161422A1 (en) Arginase 2 vaccine
JP2025538981A (ja) TGF-β1ワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260220